Krishnansu Tewari, MD
Gynecologic Oncology · Orange, CANPI 1205868445
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Merck at 29.8% of the total. Reporting peaked in 2019 at $145,271 and has fallen 77.2% since, to $33,081 in 2025. Among gynecologic oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 368 payments — averaging $1346.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$148K
- AstraZeneca$98K
- Tesaro, Inc.$73K
- GSK$62K
- Eisai Inc.$22K
- Clovis Oncology, Inc.$22K
- plus $71K from 16 others
Across 268 payments — averaging $9500.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.1M
- Takeda Pharmaceuticals U.S.A., Inc.$653K
- Seagen Inc.$187K
- Genentech, Inc.$93K
- Eisai Inc.$82K
- Genmab U.S., Inc.$63K
- plus $335K from 9 others
What the payments were for
- Consulting fees$114,93123%
- Speaking & faculty fees$286,35158%
- Travel & lodging$82,60517%
- Food & beverage$10,5822%
- Education$8600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 74 | $147,701 |
| AstraZeneca | 72 | $98,118 |
| Tesaro, Inc. | 72 | $72,553 |
| GSK | 54 | $62,234 |
| Eisai Inc. | 12 | $22,076 |
| Clovis Oncology, Inc. | 27 | $21,969 |
| Genmab U.S., Inc. | 14 | $19,749 |
| Seagen Inc. | 13 | $19,273 |
| Regeneron | 7 | $8,198 |
| Astrazeneca UK Limited | 2 | $4,110 |
| Aadi Bioscience, Inc. | 3 | $3,966 |
| Eisai CO., LTD. | 1 | $3,900 |
| EMD Serono, Inc. | 1 | $3,750 |
| Chugai Pharmaceutical Co., Ltd. | 1 | $3,040 |
| Amgen | 2 | $2,596 |
| Pfizer | 2 | $1,156 |
| Karyopharm Therapeutics Inc. | 3 | $346 |
| Corcept Therapeutics | 3 | $209 |
| Myriad Genetic Laboratories, Inc. | 1 | $125 |
| Pacira Pharmaceuticals Incorporated | 1 | $105 |
| Dysis Medical, Inc. | 1 | $77 |
| AbbVie | 2 | $76 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$495,328 in reported general payments places this provider in the 95th percentile of 152 gynecologic oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pantoprazole Sodium | 14 | $50 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Orange
- Fabio CappucciniOrange$313K
- Jill TsengOrange$14K
- John ChanSan Francisco$2M
- Dana ChaseLos Angeles$1.3M
- Ramez EskanderEncinitas$706K
- Mehdi Moslemi-KebriaUpland$225K
- Amer KaramStanford$168K
- Rebecca BrooksSacramento$133K
- Kenneth KimWest Hollywood$88K
- Oliver DorigoStanford$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.